Borden, L., Washington, C., Thomas, S., Smitherman, C., Backes, F., Cosgrove, C., … Secord, A. A. (2024). Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database. In Gynecologic Oncology (Vol. 190, pp. S98–S99). Elsevier BV. https://doi.org/10.1016/j.ygyno.2024.07.145

Borden, Lindsay, Christina Washington, Samantha Thomas, Carson Smitherman, Floor Backes, Casey Cosgrove, Paulina Haight, et al. “Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database.” In Gynecologic Oncology, 190:S98–99. Elsevier BV, 2024. https://doi.org/10.1016/j.ygyno.2024.07.145.

Borden L, Washington C, Thomas S, Smitherman C, Backes F, Cosgrove C, et al. Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database. In: Gynecologic Oncology. Elsevier BV; 2024. p. S98–9.

Borden, Lindsay, et al. “Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database.” Gynecologic Oncology, vol. 190, Elsevier BV, 2024, pp. S98–99. Crossref, doi:10.1016/j.ygyno.2024.07.145.

Borden L, Washington C, Thomas S, Smitherman C, Backes F, Cosgrove C, Haight P, Pothuri B, Brown A, Ko E, Powell K, Arend R, Harsono AA, Thaker P, Mullen M, Crafton S, Jackson A, Corr B, Wright J, Konecny G, Bae-Jump V, Podwika S, Moore K, Secord AA. Immune checkpoint inhibition for mismatch repair deficient endometrial cancer: MLH1 hypermethylation does not impact outcome in a multi-institutional retrospective database. Gynecologic Oncology. Elsevier BV; 2024. p. S98–S99.